Cargando…

Modelling X-linked Alport Syndrome With Induced Pluripotent Stem Cell-Derived Podocytes

Detalles Bibliográficos
Autores principales:	Lau, Ricky Wai Kiu, Fisher, Craig, Phan, Thanh Kha, Ozkocak, Dilara Ceyda, Selby, James, Saini, Sheetal, Mukundan, Sarvatha, Wise, Andrea F., Savige, Judith, Ho Poon, Ivan Ka, Haynes, John, Ricardo, Sharon D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589688/ https://www.ncbi.nlm.nih.gov/pubmed/34805641 http://dx.doi.org/10.1016/j.ekir.2021.07.027

Ejemplares similares

Unleashing the therapeutic potential of apoptotic bodies
por: Phan, Thanh Kha, et al.
Publicado: (2020)

Translating extracellular vesicle packaging into therapeutic applications
por: Ozkocak, Dilara C., et al.
Publicado: (2022)

Alport Syndrome With Kidney Cysts Is Still Alport Syndrome
por: Savige, Judy, et al.
Publicado: (2021)

Podocyte Depletion in Thin GBM and Alport Syndrome
por: Wickman, Larysa, et al.
Publicado: (2016)

Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome
por: Ge, Mengyuan, et al.
Publicado: (2023)

Editorial: Collagen IV nephropathies: Alport syndrome and beyond
por: Borza, Dorin-Bogdan, et al.
Publicado: (2022)

Molecular and functional characterization of urine‐derived podocytes from patients with Alport syndrome
por: Iampietro, Corinne, et al.
Publicado: (2020)

Patient-derived podocyte spheroids reveal new insights into the etiopathogenesis of Alport syndrome
por: Romero-Guevara, Ricardo, et al.
Publicado: (2023)

The Accumulation of VEGFA in the Glomerular Basement Membrane and Its Relationship with Podocyte Injury and Proteinuria in Alport Syndrome
por: Wang, Haiyan, et al.
Publicado: (2015)

Discoidin domain receptor 1 activation links extracellular matrix to podocyte lipotoxicity in Alport syndrome
por: Kim, Jin-Ju, et al.
Publicado: (2020)

Should We Diagnose Autosomal Dominant Alport Syndrome When There Is a Pathogenic Heterozygous COL4A3 or COL4A4 Variant?
por: Savige, Judy
Publicado: (2018)

The 2014 International Workshop on Alport Syndrome
por: Miner, Jeffrey H, et al.
Publicado: (2014)

The importance of clinician, patient and researcher collaborations in Alport syndrome
por: Rheault, Michelle N., et al.
Publicado: (2019)

A Systematic Review of Pathogenic COL4A5 Variants and Proteinuria in Women and Girls With X-linked Alport Syndrome
por: Gibson, Joel T., et al.
Publicado: (2022)

Heterozygous Pathogenic COL4A3 and COL4A4 Variants (Autosomal Dominant Alport Syndrome) Are Common, and Not Typically Associated With End-Stage Kidney Failure, Hearing Loss, or Ocular Abnormalities
por: Savige, Judy
Publicado: (2022)

The 2019 and 2021 International Workshops on Alport Syndrome
por: Daga, Sergio, et al.
Publicado: (2022)

Pathogenicity of missense variants affecting the collagen IV α5 carboxy non-collagenous domain in X-linked Alport syndrome
por: Gibson, Joel T., et al.
Publicado: (2022)

Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome
por: Gross, Oliver, et al.
Publicado: (2017)

Women and Alport syndrome
por: Rheault, Michelle N.
Publicado: (2011)

Alport's Syndrome in Pregnancy
por: Mehta, Suchita, et al.
Publicado: (2013)

Genotype-Phenotype Correlations for Pathogenic COL4A3–COL4A5 Variants in X-Linked, Autosomal Recessive, and Autosomal Dominant Alport Syndrome
por: Savige, Judy, et al.
Publicado: (2022)

Generation of induced pluripotent stem cells from renal tubular cells of a patient with Alport syndrome
por: Chen, Wenbiao, et al.
Publicado: (2015)

Establishment of microRNA, transcript and protein regulatory networks in Alport syndrome induced pluripotent stem cells
por: Chen, Wenbiao, et al.
Publicado: (2019)

New frontiers to cure Alport syndrome: COL4A3 and COL4A5 gene editing in podocyte-lineage cells
por: Daga, Sergio, et al.
Publicado: (2019)

Sindrome de Alport : revisión bibliográfica
por: Velasco Bello, Fernando Mario
Publicado: (1994)

Upregulated Expression of Integrin α1 in Mesangial Cells and Integrin α3 and Vimentin in Podocytes of Col4a3-Null (Alport) Mice
por: Steenhard, Brooke M., et al.
Publicado: (2012)

Alport syndrome: facts and opinions
por: Kashtan, Clifford
Publicado: (2017)

Genetic diagnosis of Alport syndrome
por: Cheong, Hae Il
Publicado: (2019)

Alport Syndrome Classification and Management
por: Warady, Bradley A., et al.
Publicado: (2020)

Novel Therapies for Alport Syndrome
por: Chavez, Efren, et al.
Publicado: (2022)

Auditory Perception in Alport’s Syndrome
por: Viveiros, Carla Mherlyn, et al.
Publicado: (2015)

Generation of functional podocytes from human induced pluripotent stem cells
por: Ciampi, Osele, et al.
Publicado: (2016)

Accelerated protocol for the differentiation of podocytes from human pluripotent stem cells
por: Bejoy, Julie, et al.
Publicado: (2021)

Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative
por: Kashtan, Clifford E., et al.
Publicado: (2012)

X-Linked and Autosomal Recessive Alport Syndrome: Pathogenic Variant Features and Further Genotype-Phenotype Correlations
por: Savige, Judith, et al.
Publicado: (2016)

Directed Differentiation of Human Pluripotent Stem Cells to Podocytes under Defined Conditions
por: Qian, Tongcheng, et al.
Publicado: (2019)

Anterior lenticonus associated with Alport syndrome
por: Jinagal, Jitender, et al.
Publicado: (2018)

Pulmonary calcinosis associated with Alport syndrome
por: Mismetti, Valentine, et al.
Publicado: (2022)

Alport Syndrome: A Comprehensive Review
por: Adone, Avanti, et al.
Publicado: (2023)

The Chemical Chaperone, PBA, Reduces ER Stress and Autophagy and Increases Collagen IV α5 Expression in Cultured Fibroblasts From Men With X-Linked Alport Syndrome and Missense Mutations
por: Wang, Dongmao, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fdd8583lakf5q55iaa8fl05to9